ClotCare: Blood Clots, Stroke, Heart Attack
Saturday, August 19, 2017
Home   |   DVT/PE   |   Blood Clots   |   Coumadin/Warfarin   |   New Patients   |   Self Testing   |   Email List   |   Donate

Pick a Topic:

Find info on a:

We subscribe to the HONcode principles of the HON Foundation. Click to verify.
ClotCare complies with the HONcode standard for trustworthy health
information:
verify here.

ClotCare is a member of the Coalition to Prevent Deep Vein Thrombosis (DVT Coalition)  ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.

Heparin Contamination

More information on the recent heparin contamination problem reported from the Center for Disease Control (CDC)

Henry I. Bussey, Pharm.D., FCCP, FAHA
December, 2008

According to theheart.org (theheart.org/viewArticle.do?primaryKey=926377&nl_id=tho03dec08), the December 3, 2008 issue of the New England Journal of Medicine contains two articles of interest on this issue. The first (1) is a report from the CDC that summarizes what has been learned by a collaborative effort to review and document potential cases of adverse effects due to contaminated heparins that were recently pulled from the market. This report also indicates that U.S. manufacturers have agreed to employ certain tests to evaluate heparins that may be contaminated with over sulfated chondroitin sulfate (the contaminant thought to be responsible for the reported adverse effects, some of which were fatal). The second article (2) suggests that, at certain threshold concentrations, over sulfated chondroitin sulfate will increase the prothrombin which, therefore, may be useful as a quick clinical test to determine if such contamination may be present when suspected.

References

  1. Blossom DB, Kallen AJ, Patel PR, et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 2008; 359:2674-2684.

  2. Alban S, Lühn S. Prothrombin time for detection of contaminated heparins. N Engl J Med 2008; 359:2732-2733.
Ask a question about blood clots or anticoagulant medications Have questions? Ask ClotCare. Send questions by email to webmaster@clotcare.org.

ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters.

Blood Clot Activities Calendar

New Postings:

Click here to view full list of new postings
ClotCare Home | New Postings | Patient Postings | Clinician Postings | Join Our Email List | Useful Web Links
CE Opportunities | Training Programs | DVT & PE Stories | Editorial Board | Financial Support
About ClotCare | DVT Coalition | Donate to ClotCare | Contact Us
Key topics discussed on ClotCare include: Blood Clots | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Atrial Fibrillation (A. Fib or AF) | Heart Attack | Stroke | Transient Ischemic Attack (TIA) | Mini Stroke | Bleeding Complications | Vascular Surgery | Surgical Blood Clot Removal | Warfarin | Coumadin | Lovenox | Low Molecular Weight Heparin (LMWH) | Heparin | Anticoagulants | Plavix | Aspirin | Antiplatelets | Blood Thinners
Copyright 2000-2014 by ClotCare. All rights reserved.
Terms, Conditions, & Privacy | Image Copyright Information
19260 Stone Oak Parkway, Suite 101 | San Antonio, TX 78258 | 210-495-4335
Send comments to webmaster@clotcare.org.
Saturday, August 19, 2017